Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)Business Wire • 02/26/26
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/25/26
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/25/26
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programsBusiness Wire • 02/25/26
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 02/20/26
Ionis updates time for fourth quarter and full year 2025 financial results webcastBusiness Wire • 02/17/26
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/11/26
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)Business Wire • 01/21/26
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue GrowthSeeking Alpha • 01/20/26
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readoutsBusiness Wire • 01/12/26
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B StudiesBenzinga • 01/07/26
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis BBusiness Wire • 01/07/26
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025Zacks Investment Research • 12/22/25
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)Business Wire • 12/02/25
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)Business Wire • 12/01/25
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/18/25
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)Business Wire • 11/14/25